Able and willing to comply with protocol requirements, in the opinion of the investigator 19. A written and voluntarily signed informed consent must be obtained from the patient or legally authorized representative, in accordance with local regulations, before the initiat ion DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 16 of 63 of any study-related procedures. The patient or legally authorized representative must be able to read and understand the ICF 3.5.2. Exclusion Criteria Potential patients who meet any of the following criteria at Screening will be excluded from the study: 1. Prior cancer chemotherapy, bevacizumab (or other VEGF/VEGFR-directed agent), or an investigational agent for recurrent/progressive GBM or prior bevacizumab as part of init ial therapy (prior chemotherapy or investigational agents are permitted as part of initial therapy; VEGF/VEGFR-directed agents are not permitted). 2. A contrast-enhancing brain tumor that is any of the following:  Multi-focal (defined as two separate areas of contrast enhancement measuring at least 1 cm in 2 planes that are not contiguous on either fluid-attenuated inversion recovery (FLAIR) or T2 sequences);  Associated with either diffuse or subependymal or leptomeningeal dissemination; or  >= 4 cm in any direction 3. Requirement of systemic corticosteroid use > 4 mg/day of dexamethasone or equivalent or requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of SL-701 treatment. 4. Surgical resection or major surgical procedure within 4 weeks prior to the start of SL- 701, or stereotactic biopsy within 7 days prior to the start of SL-701 5. Radiation therapy, local therapy (except for surgical re-section), or systemic therapy following first recurrence or PD. Excluded local therapies following first recur rence/ PD include stereotactic radiation boost, implantation of carmustine, biodegradable wafers (Gliadel), intratumoral or convection-enhanced delivery administered agents, etc. 6.